New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US ...(of Santaris Pharma A/S. Dr. Levin...)
| HOME >> BIOLOGY >> TECHNOLOGY |
of Santaris Pharma A/S.
Dr. Levin has 15 years of experience in RNA-based research and more than 25 years of experience in the pharmaceutical industry. Prior to joining Santaris Pharma A/S, Dr. Levin was Senior Vice President of Drug Development at Isis Pharmaceuticals where he was instrumental in advancing more than a dozen RNA-based antisense drugs from basic research to clinical development.
"We are pleased that Dr. Levin has joined our management team to establish operations in the US and oversee global development programs for Santaris Pharma A/S," said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. "His wealth of RNA-based research and development experience and industry knowledge will be instrumental in leveraging the Company's proprietary Locked Nucleic Acid chemistry and Drug Discovery Engine to explore new licensing opportunities and scientific collaborations, increase visibility with capital markets and attract leading scientists."
Santaris Pharma A/S recently achieved a breakthrough in medical science as the first company to advance a microRNA-targeted therapy into human clinical trials. A single-dose Phase 1 trial in healthy volunteers has now been completed and an additional Phase 1 multiple ascending-dose study is planned.
The drug SPC3649 specifically targets microRNA-122 (miR-122), a host factor for Hepatitis C virus replication. In 2008, Santaris Pharma A/S published the results of successful microRNA silencing with SPC3649 in non-human primates in Nature(1).
"Advancing the first microRNA therapy into human clinical trials is a
testament to Santaris Pharma A/S leadership in the field," said Henrik Orum,
Vice President and Chief Scientific Officer at Santaris Pharma A/S. "Our
proprietary LNA Drug Platform incorporating short single-stranded LNAs offers
higher affinity, greater specificity and remarkable potency compared to other
'/>"/>
| SOURCE Santaris Pharma A/S Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
2. Californias International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
5. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
6. Research breakthrough will lead to more accurate weather forecasts
7. OMT announces a breakthrough in the development of a novel human antibody platform
8. New drugs faster from natural compounds: A UC San Diego breakthrough
9. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
10. Light sensor breakthrough could enhance digital cameras
11. DNA2.0 Awarded US Patents for Breakthrough Gene Optimization Technology -- Company's Unique Algorithm Enables Expression Yields up to 50 Times Greater than Competing Approaches
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |